CoChat

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Open access
Haertle, Larissa, Barrio, Santiago, Munawar, Umair, Han, Seungbin, Zhou, Xiang, Vogt, Cornelia, Fernández, Rafael Alonso, Bittrich, Max, Ruiz-Heredia, Yanira, Da Viá, Matteo, Zovko, Josip, Garitano-Trojaola, Andoni, Bolli, Niccolò, Ruckdeschel, Anna, Stühmer, Thorsten, Chatterjee, Manik, Kull, Miriam, Krönke, Jan, Agirre, Xabier, Martin-Subero, Jose I., Raab, Peter, Einsele, Hermann, Rasche, Leo, Martinez-Lopez, Joaquin, Haaf, Thomas, Kortüm, K. Martin · 2021 · Blood
Cited by 49

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy. Patients respond well to initial treatment with IMiDs, but virtually all patients develop drug resistance over time, and the underlying mechanisms are poorly understood. We identified an as yet undescribed DNA hypermethylation in an active intronic CRBN enhancer. Differential hypermethylation in this region was found to be increased in healthy plasma cells, but was more pronounced in IMiD-refractory MM. Methylation significantly correlated with decreased CRBN expression levels. DNA methyltransferase inhibitor (DNTMi) in vitro experiments induced CRBN enhancer demethylation, and sensitizing effects on lenalidomide treatment were observed in 2 MM cell lines. Thus, we provide first evidence that aberrant CRBN DNA methylation is a novel mechanism of IMiD resistance in MM and may predict IMiD response prior to treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020010452

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 49

Metadata

Authors
Haertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Vogt, C., Fernández, R. A., Bittrich, M., Ruiz-Heredia, Y., Da Viá, M., Zovko, J., Garitano-Trojaola, A., Bolli, N., Ruckdeschel, A., Stühmer, T., Chatterjee, M., Kull, M., Krönke, J., Agirre, X., Martin-Subero, J. I., Raab, P., Einsele, H., Rasche, L., Martinez-Lopez, J., Haaf, T., & Kortüm, K. M.
Venue
Blood
Published
2021-11-04
Volume
138
Issue
18
Pages
1721-1726
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3168106656
Cited by
49
References
8
FWCI
4.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cereblon enhancer methylation and IMiD resistance in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.2020010452
The paper
Haertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Vogt, C., Fernández, R. A., Bittrich, M., Ruiz-Heredia, Y., Da Viá, M., Zovko, J., Garitano-Trojaola, A., Bolli, N., Ruckdeschel, A., Stühmer, T., Chatterjee, M., Kull, M., Krönke, J., Agirre, X., . . . Kortüm, K. M. (2021). Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. https://doi.org/10.1182/blood.2020010452

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.